◀ Back to CD4

CD4 — CD86

Pathways - manually collected, often from reviews:

• NCI Pathway Database TCR signaling in naïve CD4+ T cells: TCR/CD3/MHC II/CD4/LCK complex (CD3E-CD3G-CD3D-HLA-DRA-HLA-DRB1-CD4-LCK-CD247) → B7 family/CD28 complex (CD28-CD80_CD86) (modification, collaborate)
  Pelosi et al., J Biol Chem 1999, Iwashima et al., Science 1994, Chan et al., J Immunol 1994, van Oers et al., J Exp Med 1996, Tuosto et al., Eur J Immunol 1998
  Evidence: mutant phenotype, assay
• NCI Pathway Database TCR signaling in naïve CD4+ T cells: B7 family/CD28 complex (CD28-CD80_CD86) → TCR/CD3/MHC II/CD4/LCK/ZAP-70 complex (CD247-CD3E-CD3G-CD3D-HLA-DRA-HLA-DRB1-CD4-LCK-ZAP70) (modification, activates)
  Pelosi et al., J Biol Chem 1999, Iwashima et al., Science 1994, Chan et al., J Immunol 1994, van Oers et al., J Exp Med 1996, Tuosto et al., Eur J Immunol 1998
  Evidence: mutant phenotype, assay
• NCI Pathway Database TCR signaling in naïve CD4+ T cells: TCR/CD3/MHC II/CD4/LCK complex (CD3E-CD3G-CD3D-HLA-DRA-HLA-DRB1-CD4-LCK-CD247) → B7 family/CD28 complex (CD28-CD80_CD86) (modification, activates)
  Woods et al., EMBO J 2001, Wilcox et al., J Biol Chem 2003, August et al., Proc Natl Acad Sci U S A 1994, Raab et al., Proc Natl Acad Sci U S A 1995, Gibson et al., J Biol Chem 1996, Heyeck et al., J Biol Chem 1997
  Evidence: mutant phenotype, assay, physical interaction
• NCI Pathway Database TCR signaling in naïve CD4+ T cells: B7 family/CD28 complex (CD28-CD80_CD86) → TCR/CD3/MHC II/CD4 complex (CD247-CD3E-CD3G-CD3D-HLA-DRA-HLA-DRB1-CD4) (modification, activates)
  Housden et al., Eur J Biochem 2003, Barber et al., Proc Natl Acad Sci U S A 1989, van Oers et al., J Exp Med 1996, Kersh et al., Science 1998, Tuosto et al., Eur J Immunol 1998, Viola et al., Science 1999
  Evidence: mutant phenotype, assay
• NCI Pathway Database TCR signaling in naïve CD4+ T cells: TCR/CD3/MHC II/CD4/LCK complex (CD3E-CD3G-CD3D-HLA-DRA-HLA-DRB1-CD4-LCK-CD247) → B7 family/CD28 complex (CD28-CD80_CD86) (modification, activates)
  Raab et al., Proc Natl Acad Sci U S A 1995
  Evidence: mutant phenotype, assay

Text-mined interactions from Literome

Li et al., J Immunol 2006 (Glomerulonephritis) : Following i.p. immunization, CD86, but not CD80, promotes early Ag-specific TCR-transgenic DO11.10 CD4+ cell proliferation and IFN-gamma production, suggesting that CD100 expression enables full expression of CD86 and consequent CD4+ cell activation
Thottingal et al., J Allergy Clin Immunol 2006 (Peanut Hypersensitivity) : These were blocked by anti-CD4 and were dependent on CD28/CD86 costimulation
Chorny et al., Ann N Y Acad Sci 2006 (Autoimmune Diseases) : Immature DCs treated with VIP exhibit increased CD86 expression and induce CD4 ( + ) T cell proliferation
Hacquard-Bouder et al., Arthritis Rheum 2007 (Disease Models, Animal...) : Blocking lymphocyte function associated antigen 1 on T cells or blocking activated leukocyte cell adhesion molecules on DCs inhibited an equivalent proportion of conjugates from forming between B27 or control DCs and T cells, whereas blocking CD86 on DCs and blocking CD28, CD2, or CD4 on T cells inhibited a greater number of conjugates from forming with control DCs, indicating specific involvement of costimulatory molecules in the reduced formation of conjugates with B27 DCs
Edgtton et al., J Am Soc Nephrol 2008 : Blocking both CD86 and CD80 profoundly inhibited CD4 ( + ) cell proliferation, but CD86 was the dominant CD28 ligand in the early proliferative response of CD4 ( + ) cells